• Event Type: The document is a transcript of an earnings conference call for Q1 FY27 results, hosted by Anand Rathi. It was an interactive question-and-answer session following initial management remarks.
  • Date and Time: The conference call was held on Thursday, August 6, 2026 at 3.30 p.m. IST.
  • Purpose: The stated purpose was to discuss the company's financial and operational performance for the first quarter of financial year 2027 (Q1 FY27).
  • Management Participants: The following management representatives participated:
  • Mr. Burjis Godrej – Chairman Designate
  • Mr. Sunil Kataria – Chief Executive Officer and Managing Director
  • Mr. S. Varadaraj – Chief Financial Officer
  • Mr. Arijit Mukherjee – Executive Director and Chief Operating Officer – Astec LifeSciences
  • Financial Period Discussed: The call focused exclusively on the performance for Q1 FY27 (April-June 2026).
  • Forward-Looking Statements: The moderator, Mr. Nitesh Dhoot, explicitly stated that some statements made during the call may be forward-looking, and a disclaimer to this effect was included in the earnings presentation shared earlier.
  • Key Financial & Business Highlights Disclosed:
  • Consolidated Performance: Sales of INR 2,852 crores, representing 10% YoY growth.
  • Segment-wise Performance:
  • Animal Nutrition: Revenue growth of 12.6%; segment result grew 29% (underlying 36%); 15% growth in cattle feed volumes.
  • Oil Palm: Segment revenue increased 28.9%; segment result grew 14.4%; supported by higher CPO/PKO realizations and improved oil extraction efficiency (OER: 18.8% vs 18.4% in Q1 FY26).
  • Crop Care (Stand-alone): Revenue declined 16.2% due to delayed monsoon impacting volumes; margin contraction.
  • Astec LifeSciences: Sustained at EBITDA breakeven (vs INR 11 cr loss in Q1 FY26); revenue moderately lower.
  • Dairy: Revenue growth of 11.4%; value-added products salience increased from 42% to 49%.
  • Godrej Foods: Branded volumes grew ~6%; Yummiez volumes grew 22%.
  • Bangladesh JV (ACI Godrej Agrovet): Returned to double-digit growth in volumes, revenue, and PBT.
  • Guidance & Outlook:
  • Astec LifeSciences: Revenue growth guidance revised to 'at least more than 20%' for FY27.
  • Consolidated: Management expressed confidence in achieving 'double-digit growth' for FY27, with a better assessment to be provided after Q2.
  • Oil Palm: Targeting high single-digit to early double-digit FFB volume growth over the long-range plan (LRP); downstream value-addition expected to add ~200 bps to EBITDA.
  • Strategic Updates:
  • Oil Palm: Rollout of India's first integrated palm oil complex; first specialty fats refinery slated for September 2026.
  • Crop Care: Portfolio diversification with new product launches (Ashitaka - maize herbicide, Takai - paddy insecticide, Ghassnash - soybean herbicide).
  • Foods: Strategic shift to reduce live bird trading and focus on scaling up B2C branded portfolio (Yummiez, Real Good).
  • Compliance: The document is a submission to BSE and NSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript is also available on the company's website (www.godrejagrovet.com).

Additional Notes Section

  • The document provided is the full transcript of the conference call, which included a detailed Q&A session with analysts.
  • No financial data was disclosed for the first time in this announcement; it is a transcript of a call discussing previously announced results.
  • The transcript contains extensive operational and strategic details discussed by management in response to analyst questions.